These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27637306)

  • 1. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
    Riva N; Ageno W
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.
    Kim SA; Yhim HY; Bang SM
    J Korean Med Sci; 2019 Feb; 34(6):e52. PubMed ID: 30787683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Direct Oral Anticoagulants in Special Populations.
    Li A; Lopes RD; Garcia DA
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1053-71. PubMed ID: 27637307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
    Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
    Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers.
    Shimizu A; Sawada K; Shiomi M; Kawano M; Matsumoto Y; Takiuchi T; Kodama M; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Tomimatsu T; Kimura T
    Int J Gynaecol Obstet; 2019 Nov; 147(2):252-257. PubMed ID: 31420876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.
    Brekelmans MP; Kappelhof M; Nieuwkerk PT; Nierman M; Buller HR; Coppens M
    Neth J Med; 2017 Mar; 75(2):50-55. PubMed ID: 28276323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of venous thromboembolism.
    Becattini C; Manina G
    Curr Vasc Pharmacol; 2014 May; 12(3):384-92. PubMed ID: 24846227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis.
    Yamashita Y; Morimoto T; Toyota T; Shiomi H; Makiyama T; Ono K; Kimura T
    Thromb Res; 2018 Jun; 166():37-42. PubMed ID: 29655001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants.
    Legnani C; Martinelli I; Palareti G; Ciavarella A; Poli D; Ageno W; Testa S; Mastroiacovo D; Ciammaichella M; Bucherini E; Mumoli N; Cosmi B
    PLoS One; 2019; 14(7):e0219751. PubMed ID: 31310608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral anticoagulants for primary and secondary prevention of venous thromboembolism].
    Gavorník P; Dukát A; Gašpar Ľ; Gubo G; Hučková N
    Vnitr Lek; 2016; 62(9):746-750. PubMed ID: 27715076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
    Chan NC; Eikelboom JW; Weitz JI
    Circ Res; 2016 Apr; 118(9):1409-24. PubMed ID: 27126650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral anticoagulants for treatment of venous thromboembolism].
    Espinola-Klein C; Weisser G
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1162-4. PubMed ID: 21611919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology and pharmacologic treatment of venous thromboembolism.
    Bain J; Oyler DR; Smyth SS; Macaulay TE
    Curr Drug Targets; 2014 Feb; 15(2):199-209. PubMed ID: 24102472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.